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ABSTRACT (257 words)  
Aims: To determine whether the provision of contingency management using financial incentives to 
improve hepatitis B vaccine completion in people who inject drugs entering community treatment 
represents a cost-effective use of healthcare resources. 
Design: A probabilistic cost-effectiveness analysis was conducted, using a decision-tree to estimate 
the short-term clinical and healthcare cost impact of the vaccination strategies, followed by a Markov 
process to evaluate the long-term clinical consequences and costs associated with hepatitis B 
infection. 
Settings and participants: Data on attendance to vaccination from a UK cluster randomised trial. 
Intervention: Two contingency management options were examined in the trial: fixed vs. escalating 
schedule financial incentives. 
Measurement: Lifetime healthcare costs and quality-adjusted life years discounted at 3.5% annually; 
incremental cost-effectiveness ratios. 
Findings: The resulting estimate for the incremental lifetime healthcare cost of the contingency 
management strategy versus usual care was £22 (95% CI: -£12 to £40) per person offered the 
incentive. For 1,000 people offered the incentive, the incremental reduction in numbers of hepatitis B 
infections avoided over their lifetime was estimated at 19 (95% CI: 8 to 30). The probabilistic 
incremental cost per quality adjusted life year gained of the contingency management programme was 
estimated to be £6,738 (95% CI: £6,297 to £7,172), with an 89% probability of being considered cost-
effective at a threshold of £20,000 per quality-adjusted life years gained (98% at £30,000). 
Conclusions: Using financial incentives to increase hepatitis B vaccination completion in people who 
inject drugs could be a cost-effective use of healthcare resources in the UK as long as the incidence 
remains above 1.2%. 
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Many countries include universal Hepatitis B virus (HBV) vaccination in their national immunisation 
programmes(1). A few countries, including the United Kingdom (UK), have selective vaccination 
policies that target individuals at increased risk of HBV infection or complications from the disease 
including people who inject drugs or who live with injectors(2). 
Despite these immunisation programmes, HBV infections remain an important public health problem 
among people who inject drugs (PWID) even in many countries with universal HBV vaccination(3). 
In England and Wales, the prevalence of current or past infection with HBV (measured by anti-HBc 
seropositivity) in current or past injectors has declined over the last 20 years from 30% in 2003 to 
17% in 2012, due in part to the introduction of a national prison vaccination scheme in 2003(4;5). 
Monitoring data indicate that among current and past injectors in contact with specialist services, the 
self-reported hepatitis B vaccine uptake has increased from 50% in 2003 to 75% in 2012(4). Despite 
this improvement in the self-reported vaccine uptake, completion rates of HBV vaccination among 
current and past injectors, even those using specialist services, remains low, and vaccine uptake has 
plateaued in recent years(4). Public health benefits from HBV vaccination are not therefore fully 
realised in PWID and transmission continues (albeit at lower levels), with on-going potential for 
community outbreaks(6;7). Reasons for low completion of HBV vaccinations in community settings 
include the poor adherence to treatment among PWID and a high drop out from health care 
services(8). 
Contingency management has been proposed as an approach to improve patient adherence and 
completion of public health interventions among hard-to-reach groups, including HBV vaccination in 
PWID using community-based services(9;10). It uses incentives to encourage attendance, reduce 
missed appointments, and improve successful intervention uptake(9). Studies conducted in 
Australia(11) and the US(12;13) showed significantly improved adherence and completion of HBV 
vaccination using contingency management in PWID. Similar findings were observed in the UK in a 
recent 3-arm cluster randomised controlled trial where PWID (including injectors, previous injectors 
and those at risk of injecting in the future) undergoing treatment for heroin dependence were 
randomised to either HBV vaccination with or without contingency management (14). 
There have been no economic evaluations of the use of contingency management to enhance 
completion of HBV vaccination among PWID in routine drug treatment settings. This study evaluates 
whether the provision of financial incentives to improve HBV vaccination completion in PWID as 
undertaken in Weaver et al(14) represents a cost-effective use of healthcare resources.  
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METHODS 
Model 
A decision-analytic model was constructed in Microsoft Excel comprising a decision-tree to estimate 
the short-term (i.e. around vaccination attempts) clinical and cost impact of the vaccination strategies, 
followed by a Markov chain to evaluate the long-term clinical consequences and costs associated with 
HBV infection of a hypothetical cohort of PWID (including injectors, previous injectors and those at 
risk of injecting in the future as defined in the trial) undergoing treatment over the lifetime in England 
and Wales. 
The decision-analytic model compares two strategies: HBV vaccination with and without contingency 
management. Two contingency management options were examined in the trial (fixed vs. escalating 
schedule financial incentives). Data from the two options evaluated in the trial were pooled in the 
economic model in the absence of differences(14). Further details on the trial and baseline 
characteristics of patients included in the trial are available in Weaver et al(14). 
The structure of the decision tree model is presented in Fig. 1. with participants able to attend or not 
attend one, two or all three ‘required’ vaccination appointments. At the end of the HBV vaccination 
attempt, subjects within the model can be successfully vaccinated (as a result of one, two or three 
vaccine doses), or remain susceptible to HBV (as a result of failing to begin vaccination, failing to 
complete the vaccination course, or as a result of a lack of vaccine efficacy despite completing the 
course). 
[INSERT FIGURE 1] 
 
 
A Markov process (Fig. 2.), using a one year cycle length was used to simulate the long-term clinical 
and cost consequences of HBV-related infection. The model tracks progression through HBV disease 
states. Health states and transitions between health states were based on descriptions of the natural 
history of HBV infection in existing systematic reviews (15-18) and on published economic models 
including HBV(19-22). The economic model differentiates periods where individuals are at increased 
risk of HBV infection (are in the PWID population), and where individuals at lower risk of HBV 
infection (are ex-PWID). We assumed that individuals at increased risk of HBV infection have an 
ongoing rate of becoming immune to reflect the UK selective vaccination policy targeted to 
individuals at increased risk of HBV infection. 
[INSERT FIGURE 2] 
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HBV incidence 
The incidence of HBV infection among susceptible PWID in the UK was estimated at 2.16% per year 
using data from the national Unlinked Anonymous Monitoring Survey among current and past 
injectors and an approach similar to Sutton et al(23). Additional details are provided in supporting 
information. 
Direct data informing the incidence of HBV among ex-PWID are lacking: it could range from zero to 
be the same level as in PWID. The base-case assumes HBV infection incidence in ex-PWID equals 
the general population incidence. General population HBV incidence was estimated at 4.08 per 
100,000 using the annual incidence of reported acute hepatitis B in England(24) adjusted for under-
reporting and asymptomatic cases (21). 
 
Characteristics of the PWID population 
The rate at which individuals cease injecting drugs(25) was used as a proxy for the probability of 
leaving the PWID population and ceasing to be at high HBV infection risk (Table 1). PWID can also 
become protected through existing targeted vaccination programs. We estimated this rate of 
vaccination using the prevalence of self-reported HBV vaccine uptake among current and past 
injectors in 2011 (76%(4)) and converting this into the annual probability of vaccination ( 28.8%)  
assuming a constant uptake prevalence and PWID population size. To account for partial protection in 
those reporting vaccination , we assumed 47.5% of self-reported vaccinations are successful (based on 
the distribution of vaccine dose given in prison(26) and evidence on the vaccine efficacy(27)). 
The model accounts for elevated risk of all-cause mortality (Hazard Ratio 4.8; 95% confidence 
interval  [CI]: 4.6–5.0) for persons in contact with drug-treatment services compared with the general 
population. The unadjusted mortality rate in the general population by age was from UK life tables for 
England and Wales(28). 
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Natural history of HBV 
The transition probabilities characterising the natural history of HBV were derived from the published 
literature (Table 1) (15-18;29). Lacking data for PWID, transitions between HBV health states among 
the general population were used. 
[INSERT TABLE 1] 
 
 
Effectiveness of the vaccination strategies 
The economic analysis uses data from Weaver et al.(14). The primary outcome in this trial was 
vaccination completion within 28 days. Attendance rates used in the economic model are presented in 
Table 2. To reflect clinical practice, we included delayed attendance (within a 3-month window from 
the start of the trial). The same probability of attending a subsequent appointment was used 
irrespective of whether the previous vaccination was received on time. 
[INSERT TABLE 2] 
 
 
Vaccine effectiveness 
The effectiveness (sero-protection) associated with the receipt of one, two and three doses was 
obtained from the literature(27) as data were not routinely collected in the trial. In the economic 
model, we assumed that participants receiving one and three vaccine dose had a sero-protection of 
15% and 76.4% respectively,(27) averaging these for individuals receiving two doses. We assumed 
that sero-protection was conferred after the last vaccine dose (one, two or three doses), that immunity 
is lifelong, and that the last dose was within 3 months from the first. Adverse reactions to the vaccine 
are rare and were neglected(27). 
  
 
Costs 
A UK National Health Service perspective is employed and therefore only direct medical costs are 
considered. Costs are discounted at 3.5% in the base-case as per the National Institute for Health and 
Care Excellence recommendation in the UK(30). 
Staff, equipment and supervision costs were calculated from the trial, based on data collected in 10 
clinics for 116 patients enrolled in the trial irrespective of vaccination arm. The costs estimated 
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include adjustment for staff time associated with non-attendance. Staff plus equipment costs were 
estimated to be £15.68±5.65 (standard deviation - SD) for individuals attending no vaccination 
appointment, £69.29±12.66 for individuals attending only one vaccination appointment, £98.91±16.21 
for individuals attending only two vaccination appointments, and £112.35±16.30 for individuals 
attending all three vaccination appointments. The cost of training staff for contingency management 
was excluded from the base-case and the cost for Engerix (£12.99 per dose)(31) was assumed as 
benefits associated with prevention of hepatitis A were not included. People receiving contingency 
management were assumed to receive a £10 voucher per vaccination appointment attendance. Finally, 
for participants who attended at a later date an additional cost was included for every unscheduled 
vaccination, equivalent to the cost associated with non-attendance of the first vaccination appointment 
(£16). 
In the economic model, PWID have a probability of vaccination through existing targeted programs. 
A cost per patient of £82 was applied to participants receiving these vaccinations based on the 
proportion of patients receiving one, two or three doses in prison,(26) assuming a cost of £29 for 
administration/preparation/administration per dose(32) (based on 30 minute nurse time) and the cost 
per vaccine dose (£12.99 per dose)(31). 
Direct medical costs associated with the management of HBV infection are taken from the literature 
and assumptions when appropriate (supporting Table S1)(20;22;32-34). 
 
 
Utilities 
Health-related quality of life scores (utilities) are assigned to each of the modelled health states based 
on trial estimates or published literature. The baseline health utility for uninfected PWID and Ex-
PWID was estimated as 0.57±0.34 (Range: -0.43 – 1.00) based on the mean (SD) Euroqol 5 
dimensions score in trial subjects. The decrements in quality of life for patients with active chronic 
HBV, inactive chronic HBV, compensated cirrhosis, decompensated cirrhosis, hepatocellular 
carcinoma and post-liver transplant was taken from Ong et al(35) in non-PWID. Individuals with 
fulminant hepatitis were assumed to have the same decrement in quality of life as individuals with 
hepatocellular carcinoma. Similarly, the decrement in quality of life the first year following 
transplantation was taken as mean of the decrement in quality of life for patients with hepatocellular 
carcinoma and post-transplant patients (supporting Table 2). We assumed individuals with acute 
symptomatic hepatitis had a reduction in quality-adjusted life years of 0.0255 (accounting for the 
duration of illness)(36) and no reduction in quality of life for individual with asymptomatic hepatitis. 
Finally, no decrement in quality of life associated with vaccination was considered (27).  
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Analysis 
Results are presented probabilistically to take account of the simultaneous effect of uncertainty 
relating to model parameter values. A total number of 1,000 simulations were performed in order to 
provide sufficient information on uncertainty. The results of the probabilistic analysis are also 
presented as cost-effectiveness planes and acceptability curves. 
A number of one-way sensitivity analyses were conducted. Results are presented in the form of a 
Tornado diagram.  
 
 
RESULTS 
For 1,000 people offered the incentive, we estimated the number of HBV infections to be 44, 
compared with 62 in the absence of financial incentives (reduction in numbers of HBV infections of 
19; 95% CI: 8 to 30) based on our mathematical model under our base-case assumptions. 
The cost of delivering HBV vaccination (including staff costs, equipment, vaccine cost, and cost 
associated with contingency management) was estimated to be £156.73 (95% CI: £126.44 to £181.17) 
per participant receiving the intervention and £78.36 (95% CI: £52.50 to £101.62) per participant 
under treatment as usual. The model predicted that 48. 77% (95% CI: 43.08% to 52.86%) of 
participants receiving contingency management would be protected against HBV infection, compared 
with 26.54% (95% CI: 19.36% to 32.65%) for treatment as usual. 
Providing contingency management in the manner of the trial would lead to a small gain in life years 
(0.0045; 95% CI: 0.0017 to 0.0075) and quality-adjusted life years (0.0032; 95% CI: 0.0013 to 
0.0054) per patient, but at an increased cost (£21.86; 95% CI: -£12.20 to £39.86) despite the reduction 
in expected HBV management costs (-£53.34; 95% CI: -£96.24 to -£33.88) over a lifetime.  
Under our base-case assumptions, the probabilistic incremental cost-effectiveness ratio associated 
with the provision of modest financial incentives to increase vaccination completion in PWID in 
contact with specialist services was estimated to be £6,738 (95% CI: £6,297 to £7,172)  per quality-
adjusted life years gained using a lifetime horizon. 
The economic analysis was most sensitive to the time horizon, the chronicity rate following HBV 
exposure, the duration individuals remain at increased risk of HBV infection (i.e. remain PWID), the 
incidence rate for HBV, discount rates for both costs and benefits, the cost associated with 
training/supervision (Fig. 3.). 
[INSERT FIGURE 3] 
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A major uncertainty in the model relates to the incidence of HBV infection in England and Wales 
among PWID and ex-PWID. In the base-case we assumed the incidence in PWID to be around 2.16%  
(95% CI: 1.76% to 2.67%) based on results estimated from the Unlinked Anonymous Monitoring 
Survey. However, there is uncertainty around this value. Fig. 4. shows that under our current base-
case assumptions (assuming the incidence of HBV in ex-PWID to be the same as the general 
population), the incidence of HBV in PWID needs to be greater than 1.2% per year for the 
incremental cost per quality-adjusted life years gained to fall below a cost-effectiveness threshold of 
£20,000 per quality-adjusted life years gained. The incremental cost per quality-adjusted life years 
gained also improves as the incidence of HBV in ex-PWID becomes closer to the incidence in PWID 
and may lead to cost-savings (data not shown). 
   
[INSERT FIGURE 4] 
The cost-effectiveness acceptability curve and cost-effectiveness planes are presented in Fig. 5(A). 
and Fig. 5(B).. The use of contingency management have 88.51% and 97.60% probabilities of being 
considered cost-effective at a willingness to pay of £20,000 and £30,000 per quality-adjusted life 
years gained respectively under our base-case assumptions. 
[INSERT FIGURE 5(A)] 
[INSERT FIGURE 5(B)] 
   
  
This article is protected by copyright. All rights reserved. 
DISCUSSION 
Contingency management using financial incentives to improve completion of hepatitis B vaccination 
in people injecting drugs entering community-based services is likely to be cost-effective under 
current willingness to pay(30). This is the first study to undertake an economic evaluation to calculate 
the cost-effectiveness of providing contingency management - financial incentives - to PWID to 
enhance hepatitis B vaccination completion. 
Key strengths of this study include that it is based on a well-conducted cluster randomised controlled 
trial of contingency management versus treatment as usual in twelve specialist NHS services 
providing opiate substitution treatment in England(14). The trial included direct measurement of the 
costs of delivering contingency management including staff time, equipment and consumables.  
The best available evidence was used. The structure of the model follows the representation of the 
natural course of HBV in previous systematic reviews describing the natural history of HBV 
infection(15-18) and previous economic evaluations(19-22). The incidence of HBV was estimated 
from cross-sectional survey data from the national Unlinked Anonymous Monitoring Survey, which 
provide robust estimates of prevalence trends of HBV infection and self-reported vaccination among 
current and past injectors in the UK.  
The generalizability of our results requires careful consideration. The UK does not have a programme 
of universal HBV vaccination. However, intensive targeted efforts in the UK have resulted in 
improved coverage of HBV vaccination among PWID, and while the cohorts vaccinated at birth in 
countries that did implement universal programmes may now be approaching the age of first injection, 
coverage may be lowest among those most likely to inject. Similar trials conducted in Australia(11) 
and the US(12;13) showed that it is possible to significantly improve adherence to and completion of 
HBV vaccination programs using contingency management.  
Another key factor in generalizability is the existing rate of HBV incidence. Studies conducted in 
other countries such as Australia, US and Netherlands report a HBV incidence in current and past 
injectors ranging between 1.8 to 30.7 per 100 person-years, (37) but these studies are dated. There is 
also likely to be large sub-national variation. However, our sensitivity analysis suggests that the ICER 
would fall below £20,000 per QALY gained when the incidence of HBV in PWID is over 1.20% per 
year. 
As with any economic evaluation, there are some limitations. There are uncertainties on the future 
probability for a susceptible PWID to be reached by current targeted vaccination program in England 
and Wales, the duration individuals remain at increased risk of HBV infection, and the risk of HBV 
infection among ex-PWID. It is also difficult to predict sero-protection in this patient group as some 
PWIDs are protected after one vaccination and some are not even after three doses. There is also 
uncertainty around efficacy of incomplete vaccine course and the time to protection. Decrements in 
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utilities associated with hepatitis B were taken from non-UK data among non-PWID data. PWID may 
experience different decrements in quality of life due to high propensity for comorbidities. Transitions 
between HBV health states among PWID were also taken from studies conducted in cohorts that did 
not entirely comprise PWID. In order not to over-estimate the benefits of vaccination, we allowed for 
life-course reductions in risk of HBV infection by introducing an ex-PWID state. We conservatively 
assumed the risk of HBV infection among ex-PWID to be the same as the general population, in the 
absence of specific data for this group. In reality ex-PWID may have higher exposure to HBV than 
the general population, e.g. due to re-commencing injecting or sexual transmission. 
 
In the trial, contingency management was shown to increase vaccination completion rapidity, 
therefore reducing the period at risk of infection. This is not captured in the economic model. 
Similarly, attendance at scheduled appointments was increased in patients receiving the intervention; 
which may therefore reduce the workload in clinic and increase efficiency and therefore may lead to a 
reduction in costs.  
Further development of the modelling approach could consider secondary transmission 
(dynamic/transmission modelling) of HBV and the indirect effect of vaccination (herd immunity). The 
modelling presented here also does not consider outbreaks or co-infection associated with hepatitis A, 
hepatitis C and human immunodeficiency virus.  
Our work suggests further research is needed to determine whether ex-PWID carry the same risk as 
PWID. Further research is also required to understand the dynamics of PWID and secondary 
transmission as well as the natural history in PWID and impact of hepatitis B on quality of life. 
 
The central implication of our study for practice is that contingency management should be seriously 
considered as a worthwhile additional investment to improve health outcomes. The UK has seen a 
sustained programme to improve HBV vaccination coverage in high-risk groups, including offering 
HBV vaccination in syringe exchanges and prisons. Contingency managementis not a replacement for 
these efforts, but was able to additional benefits in a cost-effective manner. Provision of lower 
financial incentives may potentially be as effective, and determining the optimal incentive would be 
advantageous. In the trial, attendance at the first vaccination appointment was not different between 
the two strategies (75.4% vs 76.9%) despite different financial incentives (£5 vs £10)(14).  
Wider use of contingency managementwill require guidance and monitoring. In clinical practice, 
people may not be so thoroughly screened for eligibility, resulting in more doses given to people with 
prior immunity. PWID may also not disclose their vaccination status to be eligible to receive the 
financial incentives. This has some cost implications, as more doses may be given, but it is unclear 
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whether the additional cost is outweighed by the benefits. In practice, it is advised to take blood when 
possible and give a vaccine dose if uncertain of someone’s protective immunity.  
This economic evaluation examined the provision of HBV vaccination only. Some sites in the trial 
offered a bivalent vaccine providing protection for both HBV and hepatitis A, at little extra cost. The 
demonstrated malleability of health-adherence behaviours in this population could potentially be 
leveraged to boost other interventions for little extra cost, e.g. hepatitis C virus testing. If provided in 
parallel to HBV vaccination, or even as standalone interventions with contingency management might 
lead to more PWID tested for hepatitis C virus coming back to get their results, and more of those 
testing positive then entering a Hepatitis C virus care pathway. Evaluation of such combined 
strategies will require additional research.  
Finally, it is unclear whether results are transferable to other injectors, notably people who inject 
image and performance drugs.(38).  
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Conclusions 
This is the first economic evaluation examining the cost-effectiveness of providing contingency 
management using financial incentives - to PWID in contact with specialist services in order to 
enhance hepatitis B vaccination completion. We find that using contingency managementto increase 
vaccination completion among this group is cost-effective under current willingness to pay 
thresholds. However, there are considerable uncertainties that need fuller attention in future studies, 
notably the paucity of evidence on the incidence of HBV infection incidence and the likelihood of 
PWID being reached by existing targeted vaccination programmes such as prison vaccination in the 
future. The intervention is likely to be more cost-effective in settings with higher risk of HBV 
infection or if the occurrence of outbreaks is considered.  
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Table 1: Model parameters used for Annual transitions (unless stated) in the natural history 
Markov model 
  
Base-
case 
Lower range 
reported in 
the literature  
Upper range 
reported in the 
literature Source 
From ‘Susceptible PWID’ 
      
  
Probability of HBV infection 
2.16% 1.76% 2.67% 
Estimated from 
a catalytic 
model 
Probability of future protection± 
12.80%   
Derived from 
(4;25-27) 
Probability of leaving PWID 
population 
9.09% 5.00% 16.67% 
(25) 
Remain susceptible - PWID 
75.95%*
** 
   
From ‘Susceptible – ex PWID’ 
 
  
  
Probability of HBV infection 
0.0041% 0%* 2.16%** 
Assumption 
Remain in ‘Susceptible – ex 
PWID’ 
99.996**
*   
 Proportion of HBV infection 
that are acute, fulminant and 
chronic 
   
 Proportion of HBV infection that 
are acute (non-fulminant)‡ 
93.20%*
  
 
  
This article is protected by copyright. All rights reserved. 
** 
Proportion of HBV infection that 
are fulminant‡ 
0.55%  0.30% 0.80% 
(21) 
Proportion of HBV infection that 
are chronic‡ 
6.25% 2.50% 10.00% 
(29) 
From ‘Fulminant HBV’ 
      
  
Proportion undergoing  liver 
transplant‡ 
13.50% 10.00% 17.00% 
(20) 
Proportion of excess death‡ 
72.86% 
  
Derived from 
(21)and(15)  
Proportion of non-fatal fulminant 
HBV not undergoing liver 
transplant‡ 
13.64%*
**   
 From ‘Chronic HBV 
(HBeAg+ve)’ 
      
  
Probability of seroconversion 
(CHB -ve or inactive)  
11.50% 8.00% 15.00% 
(15-17) 
Proportion seroconvert to CHB –
ve‡ 
15.00% 10.00% 20.00% 
(15) 
Probability of developing CC 
4.00% 2.00% 6.00% 
(16-18) 
Probability of developing HCC 
0.35% 0.10% 0.60% 
(16;17) 
Probability of excess death 
0.55% 0.10% 1.00% 
(16) 
Remain in Chronic HBV 
(HBeAg+ve) 
80.10%*
**   
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From ‘Chronic HBV (HBeAg-
ve)’ 
      
  
Probability of developing CC 
9.00% 8.00% 10.00% 
(18) 
Probability of developing HCC 
0.66% 0.01% 1.30% 
(17;18) 
Probability of excess death 
0.55% 0.10% 1.00% 
(16;17) 
Remain in Chronic HBV 
(HBeAg-ve) 
89.80%*
** 
   Chronic HBV (Inactive) to: 
   
 
Probability of developing CC 
2.00% 1.00% 3.00% 
(17;18) 
Probability of developing HCC 
0.11% 0.02% 0.20% 
(17;18) 
Probability clear HbsAg 
1.25% 0.50% 2.00% 
(15) 
Probability of excess death 
0.03% 0.02% 0.04% 
(17) 
Remain in Chronic HBV 
(HBeAg inactive) 
96.61%*
** 
  
 From ‘CC’ 
   
 
Probability of developing DC 
3.50% 2.00% 5.00% 
(15-18) 
Probability of developing HCC 
2.85% 2.00% 3.70% 
(15-18) 
Probability of excess death 
3.20% 2.90% 3.50% 
(15-17) 
Remain in CC 
90.50%*
**   
 From ‘DC’ 
   
 
Probability of developing HCC 
7.50% 7.00% 8.00% 
(18) 
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Probability of undergoing LT 
4.40% 3.40% 5.40% 
(20) 
Probability of excess death 
35.00% 20.00% 50.00% 
(18) 
Remain in DC 
53.1%**
* 
   From ‘HCC’ 
   
 
Probability of undergoing LT 
1.70% 1.50% 1.90% 
(20) 
Probability of excess death 
35.00% 20.00% 50.00% 
(18) 
Remain in HCC 
63.30%*
** 
  
 From ‘LT’ 
   
 
Probability of excess death – first 
year 
21.00% 15.00% 27.00% 
(22) 
Probability of excess death – 
subsequent years 
5.00% 3.00% 7.00% 
(22) 
* assumption; ** assumed to be the same as PWID, *** remaining probabilities (One minus 
probabilities above), ± calculated from self-reported vaccination, leaving rate, number of vaccine dose 
received in prison and vaccine effectiveness, ‡ proportion   
 
PWID = People who inject drugs; HBV = hepatitis B virus; CHB = chronic hepatitis; LT = liver 
transplantation; CC = compensated cirrhosis; HCC = hepatocellular carcinoma; DC = decompensated 
cirrhosis; HBeAg  = chronic hepatitis B e antigen.  
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Table 2: Attendance at HBV vaccination appointments 
 Treatment as usual    CM   
1
st
 vaccination 
appointment 
       
Expected to attend 67   143  
Did not attend 33 49%  34 24% 
Attended on time 21 31%  97 68% 
Delayed attendance 13 19%  12 8.% 
2
nd
 vaccination 
appointment 
 
  
 
 
Expected to attend 31   105  
Did not attend 8 26%  13 12% 
Attended on time 15 48%  84 80% 
Delayed attendance 8 26%  8 8% 
3
rd
 vaccination 
appointment 
 
  
 
 
Expected to attend 22   85  
Did not attend 8 36.%  15 18% 
Attended on time 7 32%  64 75% 
Delayed attendance 7 32%  6 7% 
HBV = hepatitis B virus; CM = Contingency Management 
It should be noted that the number of individual expected to attend is different to the number of 
individuals who attended the previous round as some individuals were already immune and therefore 
did not need to return for another vaccine dose. 
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CM = Contingency Management; DNA = Do Not Attend; TAU = treatment as usual; V1 = 1
st
 
vaccination appointment; V2 = 2
nd
 vaccination appointment; V3 = 3
rd
 vaccination appointment  
 
Fig. 1. Decision tree model for hepatitis B vaccination strategies. Back circle represent a decision 
node.
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CC = compensated cirrhosis ; CHB = chronic hepatitis; DC = decompensated cirrhosis; HBeAg  = 
chronic hepatitis B e antigen; HBV = hepatitis B virus; HCC = hepatocellular carcinoma; LT = liver 
transplantation; PWID = People who inject drugs 
 
Fig. 2. Markov model of the long-term natural history of HBV infection. Transition between 
health states. People can die from general causes (age-specific) in any of the health states (not shown 
here). Boxed in Grey indicate excess mortality 
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CC = compensated cirrhosis; CM = contingency management; HBV = hepatitis B virus; PWID = 
People who inject drugs 
 
Fig. 3. Univariate sensitivity analysis (most sensitive parameters). White line represent the base-
case probabilistic ICER. 
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CM = contingency management; HBV = hepatitis B virus; ICER = incremental cost-effectiveness 
ratio; QALY = quality adjusted life years; TAU = treatment as usual; WTP = willingness to pay 
 
Fig. 4. Effect of varying the base-case incidence of HBV infection in PWID on the incremental 
cost per QALY gained of CM versus TAU. The blue solid line represents the ICER for CM 
compared with TAU assuming different incidence of Hepatitis B. The black dashed line represents the 
£20,000 per QALY gained WTP threshold. 
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CM = contingency management; QALY = quality adjusted life years; TAU = treatment as usual; 
WTP = willingness to pay 
 
Fig. 5(A). Cost effectiveness acceptability curves for the probability that CM is more cost 
effective than usual care. The blue solid line represents the probability for CM to be cost-effective at 
different WTP threshold. The red solid line represents the probability for TAU to be cost-effective at 
different WTP threshold. The black dashed line represents the £20,000 per QALY gained WTP 
threshold. 
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CM = contingency management; QALY = quality adjusted life years; TAU = treatment as usual; 
WTP = willingness to pay 
Fig. 5(B). Cost effectiveness plane for CM vs. TAU. Solid points represent incremental cost and 
QALY results (intervention arm minus control arm) from the probabilistic analysis for each of the 
1000 samples. The black dashed line represents the £20,000 per QALY gained WTP threshold. 
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